MRC1 and cancer: Targeting of the most abundant non-cancer cells within TME, CAFs and CD206+ macrophages, was confirmed by immunohistochemistry performed on CT26 tumors collected 24 hrs after Al647-pHLIP-STINGa administration (Figure 2F).